Methods | The National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines is an ongoing, voluntary, quality improvement registry of consecutive patients with MI treated at participating centers across the United States. Registry design, inclusion and exclusion criteria, and data definitions have been described. 3 Institutional review boards at participating hospitals approved the registry, and informed consent was waived. Trained abstractors determined registry data, including trial partici- Patients with missing or incomplete data for classification of trial participation (n = 472) or eligibility (n = 48 869) were excluded. There were no clinically relevant differences between patients included and excluded. Trial participation was defined as patients who provided informed consent and enrolled in a trial during hospitalization, even if the investigational medication, device, or procedure was never initiated.
Among nonparticipants, we determined whether trial exclusion criteria were met for 3 antiplatelet therapy trials in patients with MI during the study period, 4-6 including age younger than 18 years, uncontrolled hypertension (systolic blood pressure >180 mm Hg), stage 5 kidney disease or dialysis-dependent renal failure, cardiogenic shock, major bleeding within 24 hours of presentation, impaired hemostasis (international normalized ratio [INR] >1.5), severe anemia (hemoglobin <10 g/dL), or use of fibrinolytic therapy. Patients were classified as eligible nonparticipants for an MI trial if they met none of the exclusion criteria, as inclusion criteria for these trials were otherwise similar to registry eligibility. Mortality and cardiovascular event rates in participants were compared with eligible and ineligible nonparticipants. Logistic regression models used generalized estimating equations to determine the multivariable association between trial participation classification and in-hospital outcomes.
3 Two-sided P < .05 was considered significant. Statistical analyses were performed with SAS software version 9.3 (SAS Institute Inc). Trial participants were younger, with less previous cardiovascular disease, lower predicted risk of mortality, shorter hospital stays, and more frequent treatment with evidencebased therapy than nonparticipants ( Table 1) .
Common reasons for ineligibility included uncontrolled hypertension (42%), elevated INR (20%), severe anemia (15%), and cardiogenic shock (14%). In-hospital mortality was lowest for trial participants (1.5%), intermediate among eligible nonparticipants (2.5%) (adjusted odds ratio [OR], 1.63 [95% CI, 1.11-2.41]; P = .01), and highest among ineligible patients (8.4%) (adjusted OR, 1.91 [95% CI, 1.29-2.83]; P = .001) ( Table 2) .
Discussion | Within this registry, trial participation was infrequent and declined during the study period, yet 2 of 3 patients with MI were potentially eligible for a randomized clinical trial. Trial participants had a lower risk profile and a more favorable prognosis compared with the broader population with MI, particularly patients eligible for but not enrolled in a clinical trial.
Several limitations are noted. A quarter of registry patients enrolled during the study period were not analyzed, primarily due to a missing initial INR measurement or fibrinolytic status. Participating registry hospitals represented approximately 5% of US acute care hospitals, and half of all par- signs and symptoms at presentation (heart failure, heart rate, systolic blood pressure, electrocardiographic findings), medical history (hypertension, diabetes mellitus, current or recent tobacco use, hypercholesterolemia, and prior myocardial infarction, coronary revascularization, heart failure, stroke, and peripheral artery disease), laboratory results (baseline hemoglobin, serum creatinine, and troponin ratio to the upper limit of the local assay normal reference), medical insurance type, and within-center correlation and clustering of variable responses using an exchangeable correlation structure covariance matrix.
e A major bleeding event was defined as bleeding that occurred within the first 24 hours of admission and was a criterion for trial ineligibility. f Adjusted for demographic variables (age, sex, ethnicity/race, and weight), signs and symptoms at presentation (heart failure, heart rate, systolic blood pressure, electrocardiographic findings), medical history (hypertension, diabetes mellitus, current or recent tobacco use, hypercholesterolemia, and prior myocardial infarction, coronary revascularization, heart failure, stroke, and peripheral artery disease), laboratory results (baseline hemoglobin and serum creatinine), home mediations (aspirin, clopidogrel, warfarin, β-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aldosterone antagonist, statin, and other lipid-lowering therapy), medical insurance type, and within-center correlation and clustering of variable responses using an exchangeable correlation structure covariance matrix.
ticipating registry hospitals enrolled at least 1 patient in a clinical trial during the study period, potentially limiting extrapolation to nonparticipating hospitals. Information about socioeconomic status, individual trials, and protocol inclusion or exclusion criteria were not available. Lack of information on the specific timing and reason for trial participation at the patient, physician, and hospital level limited determination of the cause for infrequent trial enrollment, such as patients refusing to participate, researchers not enrolling patients, or no trial being conducted at the hospital. Efforts to improve trial participation are needed to enhance generalizability of results. Nesting trials within existing registries may help meet this goal.
